Biogen Inc.
Every calculator, already run for BIIB
Open the full toolkit →You have the numbers on BIIB. Get the argument.
A written report on which of these readings actually decide the outcome for Biogen Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
35 analysts covering BIIBAnalyst Price Target Disagreement for Biogen Inc.
Wall Street's bull case implies +35% from the current price; the bear case implies -26%. A 61% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for BIIB
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat no…
BIIB — frequently asked
Is BIIB a buy right now?
Wall Street's consensus rating on Biogen Inc. is Buy across 35 analysts, with a mean price target of $235.57 (+6% vs. the current $221.56). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is BIIB overvalued?
BIIB trades at 39.4x trailing earnings, against a DCF fair value of $333 per share. The current price implies 1% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is BIIB's next earnings date?
Biogen Inc. is next scheduled to report earnings around Oct 29, 2026. A full BIIB research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Biogen Inc.?
Analysts covering Biogen Inc. (BIIB) range from a bear-case target of $165.00 to a bull-case high of $300.00, with a mean consensus target of $235.57 across 31 analysts. The spread of $135.00 (61% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Biogen Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Biogen Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full BIIB research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Biogen Inc., in minutes. 3 free reports included with every account — no credit card required.